Addex Therapeutics Ltd(ADXN)Earnings, Financials & Key Ratios
ADXN•NASDAQ
Price updated Jun 19, 2026
AboutAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Show more
- Revenue$30K-92.6%
- EBITDA-$3M-12.5%
- Net Income-$7M-195.4%
- EPS (Diluted)-6.88-181.9%
- Gross Margin100%
- EBITDA Margin-9362.49%-1416.3%
- Operating Margin-9390.76%-1277.3%
- Net Margin-22448.44%-1385.7%
- ROE-93.16%-171.4%
ADXN Key Insights
Addex Therapeutics Ltd (ADXN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 61.6% over 5 years
- ✗Shares diluted 14.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ADXN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADXN Price & Volume
Addex Therapeutics Ltd (ADXN) stock price & volume — 10-year historical chart
Loading chart...
ADXN Growth Metrics
Addex Therapeutics Ltd (ADXN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-2.92%
5 Years-61.65%
3 Years-72.38%
TTM-83.58%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-195.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-187.8%
Return on Capital
10 Years-102.95%
5 Years-66.01%
3 Years-50.43%
Last Year-37.42%
ADXN Peer Comparison
Addex Therapeutics Ltd (ADXN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 NBIX | 15.89B | 158.29 | 33.90 | 21.45% | 21.55% | 21.64% | 0.13 | |
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 ANIK | 193.24M | 14.42 | -18.97 | -5.91% | -9.52% | -7.74% | 0.17 | |
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare ADXN vs Peers
Addex Therapeutics Ltd (ADXN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADXN Income Statement
Addex Therapeutics Ltd (ADXN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 499.89K | 6.04M | 2.76M | 3.61M | 2.92M | 1.42M | 1.61M | 404.1K | 29.97K |
Revenue Growth % | 2784.72% | 1109.03% | -54.29% | 30.77% | -19.28% | -51.22% | 13.39% | -74.95% | -92.58% |
Cost of Goods Sold | 29.76K | 144.17K | 230.1K | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | 5.95% | 2.39% | 8.33% | - | - | - | - | - | - |
Gross Profit | 470.13K▲ 0% | 5.9M▲ 1154.9% | 2.53M▼ 57.1% | 3.61M▲ 42.6% | 2.92M▼ 19.3% | 1.42M▼ 51.2% | 1.61M▲ 13.4% | 404.1K▼ 74.9% | 29.97K▼ 92.6% |
Gross Margin % | 94.05% | 97.61% | 91.67% | 100% | 100% | 100% | 100% | 100% | 100% |
Gross Profit Growth % | - | 1154.91% | -57.07% | 42.65% | -19.28% | -51.22% | 13.39% | -74.95% | -92.58% |
Operating Expenses | 3.24M | 7.47M | 17.14M | 15.86M | 18.42M | 11.96M | 3.86M | 3.16M | 2.84M |
OpEx % of Revenue | 647.15% | 123.57% | 620.27% | 438.88% | 631.7% | 841.04% | 239.06% | 781.82% | 9490.76% |
Selling, General & Admin | 2.2M | 4.72M | 4.31M | 5.75M | 7.75M | 3.26M | 2.03M | 1.68M | 1.89M |
SG&A % of Revenue | 439.31% | 78.05% | 155.96% | 159.13% | 265.62% | 229.33% | 125.92% | 414.54% | 6298.98% |
Research & Development | 841.31K | 2.37M | 12.45M | 10.37M | 9.01M | 7.88M | 942.71K | 435.19K | 190.19K |
R&D % of Revenue | 168.3% | 39.19% | 450.77% | 287.12% | 309.09% | 554.23% | 58.45% | 107.69% | 634.56% |
Other Operating Expenses | 197.67K | 382.99K | 374.01K | -266.32K | 1.66M | 817.79K | 882.25K | 1.05M | 766.45K |
Operating Income | -3.24M▲ 0% | -1.42M▲ 56.0% | -14.6M▼ 925.1% | -12.24M▲ 16.2% | -15.51M▼ 26.6% | -10.54M▲ 32.0% | -2.24M▲ 78.7% | -2.76M▼ 22.8% | -2.81M▼ 2.2% |
Operating Margin % | -647.15% | -23.57% | -528.59% | -338.88% | -531.7% | -741.04% | -139.06% | -681.82% | -9390.76% |
Operating Income Growth % | -3.37% | 55.96% | -925.12% | 16.17% | -26.65% | 32.02% | 78.72% | -22.84% | -2.15% |
EBITDA | -3.22M | -1.42M | -14.27M | -11.86M | -15.16M | -10.22M | -1.94M | -2.5M | -2.81M |
EBITDA Margin % | -644.1% | -23.52% | -516.51% | -328.4% | -519.78% | -718.33% | -120.09% | -617.45% | -9362.49% |
EBITDA Growth % | -3.74% | 55.85% | -903.76% | 16.86% | -27.76% | 32.59% | 81.04% | -28.81% | -12.46% |
D&A (Non-Cash Add-back) | 15.25K | 2.94K | 333.84K | 378.75K | 347.61K | 323.14K | 305.95K | 260.12K | 8.47K |
EBIT | -3.24M | -1.51M | -14.65M | -12.79M | -15.29M | -10.78M | -2.5M | -4.91M | -6.84M |
Net Interest Income | 0 | -134.31K | -91.64K | -34.2K | -57.69K | -19.65K | 42.36K | 5.62K | -2.42K |
Interest Income | 0 | 85.87K | 36.87K | 35.3K | 5.32K | 29.25K | 63.96K | 9.16K | 0 |
Interest Expense | 45.35K | 220.17K | 128.52K | 69.5K | 63.01K | 48.9K | 21.61K | 3.55K | 2.42K |
Other Income/Expense | -45.35K | -220.17K | -176.45K | -615.33K | 154K | -263.06K | -257.19K | -2.15M | -4.03M |
Pretax Income | -3.28M▲ 0% | -1.64M▲ 49.9% | -14.78M▼ 798.6% | -12.86M▲ 13.0% | -15.35M▼ 19.4% | -10.8M▲ 29.6% | -2.5M▲ 76.9% | -4.91M▼ 96.4% | -6.84M▼ 39.4% |
Pretax Margin % | -656.22% | -27.21% | -534.98% | -355.92% | -526.42% | -759.54% | -155% | -1214.88% | -22829.93% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.28M▲ 0% | -1.64M▲ 49.9% | -14.78M▼ 798.6% | -12.86M▲ 13.0% | -15.35M▼ 19.4% | -20.8M▼ 35.5% | -10.56M▲ 49.3% | 7.06M▲ 166.8% | -6.73M▼ 195.4% |
Net Margin % | -656.22% | -27.21% | -534.98% | -355.92% | -526.42% | -1462.57% | -654.47% | 1746.04% | -22448.44% |
Net Income Growth % | -4.16% | 49.86% | -798.63% | 13% | -19.39% | -35.52% | 49.26% | 166.84% | -195.36% |
Net Income (Continuing) | -3.28M | -1.64M | -14.78M | -12.86M | -15.35M | -10.8M | -2.5M | -4.91M | -6.84M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -10M | -8.06M | 11.97M | 114.34K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -30.00▲ 0% | -8.47▲ 71.8% | -67.20▼ 693.4% | -57.60▲ 14.3% | -54.00▲ 6.3% | -55.20▼ 2.2% | -16.80▲ 69.6% | 8.40▲ 150.0% | -6.88▼ 181.9% |
EPS Growth % | 10.71% | 71.77% | -693.39% | 14.29% | 6.25% | -2.22% | 69.57% | 150% | -181.9% |
EPS (Basic) | -30.00 | -8.47 | -67.20 | -57.60 | -54.00 | -55.20 | -16.80 | 8.40 | -6.88 |
Diluted Shares Outstanding | 107.84K | 194.11K | 220.24K | 222.35K | 284.33K | 376.54K | 619.23K | 817.61K | 935K |
Basic Shares Outstanding | 107.84K | 194.11K | 220.24K | 222.35K | 284.33K | 376.54K | 619.23K | 817.61K | 935K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ADXN Balance Sheet
Addex Therapeutics Ltd (ADXN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.05M | 42.15M | 32.39M | 19.49M | 21.94M | 7.83M | 4.23M | 3.54M | 1.68M |
Cash & Short-Term Investments | 2.59M | 41.68M | 31.55M | 18.76M | 20.5M | 6.96M | 3.87M | 3.35M | 1.64M |
Cash Only | 2.59M | 41.67M | 31.54M | 18.7M | 20.48M | 6.96M | 3.87M | 3.34M | 1.64M |
Short-Term Investments | 0 | 7.98K | 13.97K | 64.93K | 17.14K | 3.17K | 848 | 6.5K | 5.13K |
Accounts Receivable | 303.88K | 273.02K | 118.03K | 68.37K | 324.42K | 598.32K | 151.27K | 15.51K | 20.11K |
Days Sales Outstanding | 221.88 | 16.49 | 15.59 | 6.91 | 40.6 | 153.53 | 34.23 | 14.01 | 244.89 |
Inventory | 0 | 0 | -13.97K | 162.84K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 13.97K | 0 | 0 | 0 | 0 | 7.97K | 0 |
Total Non-Current Assets | 9.84K | 63.27K | 639.88K | 692.25K | 600.01K | 453.09K | 407.28K | 7.14M | 4.69M |
Property, Plant & Equipment | 2.75K | 8.87K | 570.97K | 633.1K | 542.1K | 398.73K | 352.94K | 42.71K | 34.27K |
Fixed Asset Turnover | 181.71x | 681.54x | 4.84x | 5.71x | 5.38x | 3.57x | 4.57x | 9.46x | 0.87x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 7.09K | 54.4K | 0 | 0 | 0 | 0 | 0 | 7.09M | 4.65M |
Other Non-Current Assets | 0 | 0 | 68.91K | 59.14K | 57.91K | 54.35K | 54.34K | 7.09K | 7.09K |
Total Assets | 3.06M▲ 0% | 42.21M▲ 1278.1% | 33.03M▼ 21.8% | 20.18M▼ 38.9% | 22.54M▲ 11.7% | 8.28M▼ 63.3% | 4.64M▼ 44.0% | 10.68M▲ 130.0% | 6.37M▼ 40.4% |
Asset Turnover | 0.16x | 0.14x | 0.08x | 0.18x | 0.13x | 0.17x | 0.35x | 0.04x | 0.00x |
Asset Growth % | 82.02% | 1278.1% | -21.76% | -38.9% | 11.69% | -63.26% | -43.95% | 130.04% | -40.38% |
Total Current Liabilities | 1.48M | 2.33M | 5.68M | 3.62M | 4.13M | 3.28M | 2.89M | 802.09K | 1.2M |
Accounts Payable | 383.21K | 1.15M | 2.22M | 983.54K | 1.79M | 1.28M | 984.38K | 253.29K | 603.59K |
Days Payables Outstanding | 4.7K | 2.91K | 3.52K | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 439.02K | 212.74K | 1.11M | 820.15K | 0 | 0 | 234.98K | 0 | 0 |
Other Current Liabilities | 439.02K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44.47K |
Current Ratio | 2.07x | 18.06x | 5.70x | 5.38x | 5.31x | 2.39x | 1.46x | 4.42x | 1.40x |
Quick Ratio | 2.07x | 18.06x | 5.70x | 5.34x | 5.31x | 2.39x | 1.46x | 4.42x | 1.40x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 243.86K | 639.35K | 1.82M | 1.95M | 1.48M | 87.03K | 603.14K | 198.94K | 399.07K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 177.22K | 258.79K | 194.32K | 87.03K | 70.38K | 34.69K | 27.04K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 243.86K | 639.35K | 1.48M | 1.69M | 1.28M | 0 | 443.52K | 164.25K | 372.03K |
Total Liabilities | 1.72M | 2.97M | 7.5M | 5.57M | 5.61M | 3.37M | 3.5M | 1M | 1.6M |
Total Debt | 0 | 0 | 550.25K | 567.4K | 482.01K | 373.13K | 344.34K | 41.99K | 34.73K |
Net Debt | -2.59M | -41.67M | -30.99M | -18.13M | -20M | -6.58M | -3.52M | -3.3M | -1.61M |
Debt / Equity | - | - | 0.02x | 0.04x | 0.03x | 0.08x | 0.30x | 0.00x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | -71.34x | -6.86x | -114.01x | -184.01x | -242.63x | -220.38x | -115.53x | -1383.08x | -2825.35x |
Total Equity | 1.34M▲ 0% | 39.24M▲ 2822.9% | 25.52M▼ 35.0% | 14.61M▼ 42.8% | 16.93M▲ 15.9% | 4.91M▼ 71.0% | 1.15M▼ 76.7% | 9.68M▲ 744.8% | 4.77M▼ 50.7% |
Equity Growth % | 514.17% | 2822.9% | -34.96% | -42.76% | 15.89% | -70.98% | -76.68% | 744.83% | -50.74% |
Book Value per Share | 12.45 | 202.16 | 115.89 | 65.71 | 59.55 | 13.05 | 1.85 | 11.84 | 5.10 |
Total Shareholders' Equity | 1.34M | 39.24M | 25.52M | 14.61M | 16.93M | 4.91M | 1.15M | 9.68M | 4.77M |
Common Stock | 13.42M | 28.56M | 32.85M | 32.85M | 49.27M | 1.15M | 1.84M | 1.84M | 2.19M |
Retained Earnings | -284.42M | -286.07M | -300.85M | -313.71M | -329.06M | -349.86M | -360.42M | -353.36M | -360.5M |
Treasury Stock | 0 | 0 | 0 | -6.08M | -11.7M | -6.28M | -909.57K | -869.71K | -1.02M |
Accumulated OCI | 7.55M | 10.27M | 7.15M | 14.66M | 24.44M | 25.77M | 29.81M | 31.06M | 96.49M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADXN Cash Flow Statement
Addex Therapeutics Ltd (ADXN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.13M | 1.75M | -9.48M | -12.18M | -14.71M | -16.44M | -7.99M | -5.37M | -2.08M |
Operating CF Margin % | -427.08% | 28.98% | -343.2% | -337.13% | -504.24% | -1155.56% | -495.51% | -1329.75% | -6925.87% |
Operating CF Growth % | 20.76% | 182.05% | -641.3% | -28.45% | -20.73% | -11.78% | 51.38% | 32.77% | 61.37% |
Net Income | -3.28M | -1.64M | -14.78M | -12.86M | -15.35M | -20.8M | -10.56M | 7.06M | -6.53M |
Depreciation & Amortization | 15.25K | 2.94K | 333.84K | 378.75K | 347.61K | 323.14K | 305.95K | 260.12K | 8.09K |
Stock-Based Compensation | 800.19K | 2.3M | 1.69M | 1.18M | 1.18M | 3.68M | 1.79M | 0 | 0 |
Deferred Taxes | 19.52K | 20.01K | 96.53K | -27.72K | -150.59K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 45.35K | 331.93K | 523.88K | 972.63K | 32.93K | 204.13K | 249.64K | -11.46M | 3.93M |
Working Capital Changes | 265.15K | 742.72K | 2.66M | -1.82M | -761.57K | 157.68K | 213.76K | -1.23M | 524.65K |
Change in Receivables | -83.16K | 30.87K | 154.99K | 49.66K | -96.41K | -252.09K | 306.51K | 134.01K | -4.37K |
Change in Inventory | 0 | 0 | -2.12M | 1.54M | -883.84K | 427.39K | 0 | 0 | 0 |
Change in Payables | -212.13K | 1.08M | 1.97M | -1.59M | 883.84K | -427.39K | -682.36K | -1.3M | 373.64K |
Cash from Investing | -697 | -61.74K | -43.25K | -59.41K | -30.31K | 2.97K | -6.84K | 4.65M | -650.08K |
Capital Expenditures | -697 | -9.05K | -28.46K | -59.41K | -31.55K | -581 | -6.84K | -1.27K | 0 |
CapEx % of Revenue | 0.14% | 0.15% | 1.03% | 1.64% | 1.08% | 0.04% | 0.42% | 0.32% | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -473.27K | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -5.37K | 0 | 0 | 0 | 0 | 0 | 5.12M | -376.98K |
Cash from Financing | 3.36M | 37.39M | -463.69K | 46.4K | 16.4M | 3.1M | 5.26M | 104.92K | 1.13M |
Debt Issued (Net) | 0 | 0 | -316.79K | -367.41K | -309.62K | -288.08K | -281.79K | -73.69K | -7.31K |
Equity Issued (Net) | 3.38M | 40.48M | 5.99K | 720.01K | 13.96M | 1.68M | 2.35M | 240.9K | 1.14M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -5.37K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -25.74K | -3.1M | -152.89K | -306.2K | 2.75M | 1.71M | 3.2M | -62.29K | 328 |
Net Change in Cash | 1.17M▲ 0% | 39.09M▲ 3229.2% | -10.13M▼ 125.9% | -12.84M▼ 26.7% | 1.79M▲ 113.9% | -13.53M▼ 855.8% | -3.09M▲ 77.1% | -523.74K▲ 83.1% | -1.28M▼ 145.2% |
Free Cash Flow | -2.14M▲ 0% | 1.74M▲ 181.6% | -9.51M▼ 645.7% | -12.24M▼ 28.7% | -14.74M▼ 20.4% | -16.44M▼ 11.5% | -8M▲ 51.3% | -5.37M▲ 32.8% | -2.08M▲ 61.4% |
FCF Margin % | -427.22% | 28.83% | -344.23% | -338.78% | -505.32% | -1155.61% | -495.94% | -1330.07% | -6925.88% |
FCF Growth % | 21.07% | 181.6% | -645.75% | -28.69% | -20.4% | -11.54% | 51.34% | 32.81% | 61.38% |
FCF per Share | -19.80 | 8.98 | -43.18 | -55.05 | -51.83 | -43.65 | -12.92 | -6.57 | -2.22 |
FCF Conversion (FCF/Net Income) | 0.65x | -1.07x | 0.64x | 0.95x | 0.96x | 0.79x | 0.76x | -0.76x | 0.31x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADXN Key Ratios
Addex Therapeutics Ltd (ADXN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -334.54% | -420.26% | -8.11% | -45.64% | -64.08% | -97.35% | -190.48% | -348.48% | 130.39% | -93.16% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | -103.27% | -44.26% |
Gross Margin | - | 94.05% | 97.61% | 91.67% | 100% | 100% | 100% | 100% | 100% | 100% |
Net Margin | -18174.08% | -656.22% | -27.21% | -534.98% | -355.92% | -526.42% | -1462.57% | -654.47% | 1746.04% | -22448.44% |
Debt / Equity | - | - | - | 0.02x | 0.04x | 0.03x | 0.08x | 0.30x | 0.00x | 0.01x |
Interest Coverage | -453.85x | -71.34x | -6.86x | -114.01x | -184.01x | -242.63x | -220.38x | -115.53x | -1383.08x | -2825.35x |
FCF Conversion | 0.86x | 0.65x | -1.07x | 0.64x | 0.95x | 0.96x | 0.79x | 0.76x | -0.76x | 0.31x |
Revenue Growth | -57% | 2784.72% | 1109.03% | -54.29% | 30.77% | -19.28% | -51.22% | 13.39% | -74.95% | -92.58% |
Related:ADXN Dividend History·ADXN Revenue History·ADXN Price History·ADXN P/E History·ADXN Financial Ratios·ADXN Institutional Holders
ADXN Frequently Asked Questions
Addex Therapeutics Ltd (ADXN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Addex Therapeutics Ltd (ADXN) reported $0.1M in revenue for fiscal year 2025. This represents a 99% decrease from $4.7M in 2006.
Addex Therapeutics Ltd (ADXN) saw revenue decline by 92.6% over the past year.
Addex Therapeutics Ltd (ADXN) reported a net loss of $6.7M for fiscal year 2025.
Dividend & Returns
Addex Therapeutics Ltd (ADXN) has a return on equity (ROE) of -93.2%. Negative ROE indicates the company is unprofitable.
Addex Therapeutics Ltd (ADXN) had negative free cash flow of $2.2M in fiscal year 2025, likely due to heavy capital investments.